Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 57 | 2025 | 429 | 12.740 |
Why?
|
| Substance Abuse, Intravenous | 12 | 2025 | 30 | 4.200 |
Why?
|
| Substance-Related Disorders | 11 | 2025 | 140 | 3.330 |
Why?
|
| Rural Population | 10 | 2025 | 297 | 2.930 |
Why?
|
| Alcoholism | 9 | 2025 | 103 | 2.920 |
Why?
|
| Alcohol Drinking | 9 | 2025 | 260 | 2.820 |
Why?
|
| Anti-HIV Agents | 9 | 2023 | 61 | 2.720 |
Why?
|
| Drug Users | 7 | 2025 | 15 | 1.740 |
Why?
|
| Adult | 47 | 2025 | 10015 | 1.670 |
Why?
|
| Medication Adherence | 6 | 2021 | 163 | 1.670 |
Why?
|
| Malawi | 15 | 2025 | 22 | 1.620 |
Why?
|
| Anti-Retroviral Agents | 7 | 2021 | 22 | 1.510 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2025 | 47 | 1.510 |
Why?
|
| Humans | 83 | 2025 | 34474 | 1.440 |
Why?
|
| Sexual Behavior | 9 | 2021 | 129 | 1.370 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 2023 | 16 | 1.330 |
Why?
|
| Female | 53 | 2025 | 21490 | 1.330 |
Why?
|
| Motivation | 4 | 2021 | 122 | 1.320 |
Why?
|
| Male | 48 | 2025 | 20697 | 1.200 |
Why?
|
| Social Support | 5 | 2025 | 195 | 1.180 |
Why?
|
| Pharmaceutical Preparations | 4 | 2021 | 40 | 1.160 |
Why?
|
| Qualitative Research | 4 | 2025 | 199 | 1.140 |
Why?
|
| Young Adult | 18 | 2024 | 2825 | 1.090 |
Why?
|
| Mass Screening | 5 | 2024 | 268 | 1.030 |
Why?
|
| Vietnam | 19 | 2023 | 24 | 1.020 |
Why?
|
| Opioid-Related Disorders | 6 | 2024 | 69 | 0.980 |
Why?
|
| Risk Reduction Behavior | 3 | 2025 | 129 | 0.940 |
Why?
|
| Disclosure | 3 | 2022 | 33 | 0.910 |
Why?
|
| Condoms | 3 | 2021 | 34 | 0.890 |
Why?
|
| Resilience, Psychological | 1 | 2025 | 21 | 0.870 |
Why?
|
| Ohio | 8 | 2025 | 64 | 0.840 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2022 | 177 | 0.830 |
Why?
|
| Needle-Exchange Programs | 3 | 2020 | 3 | 0.830 |
Why?
|
| Adaptation, Psychological | 1 | 2025 | 145 | 0.820 |
Why?
|
| Cross-Sectional Studies | 14 | 2025 | 1607 | 0.810 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2018 | 32 | 0.800 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2020 | 35 | 0.790 |
Why?
|
| Clinical Trials as Topic | 1 | 2025 | 325 | 0.770 |
Why?
|
| Hepatitis C | 2 | 2024 | 45 | 0.740 |
Why?
|
| Contact Tracing | 2 | 2023 | 9 | 0.740 |
Why?
|
| HIV Seropositivity | 2 | 2022 | 14 | 0.680 |
Why?
|
| Depressive Disorder, Major | 1 | 2021 | 41 | 0.680 |
Why?
|
| Depression | 11 | 2023 | 458 | 0.670 |
Why?
|
| Kentucky | 5 | 2025 | 17 | 0.670 |
Why?
|
| Counseling | 6 | 2025 | 99 | 0.670 |
Why?
|
| Syringes | 1 | 2020 | 5 | 0.650 |
Why?
|
| Sexual Partners | 8 | 2023 | 37 | 0.640 |
Why?
|
| Patient Preference | 1 | 2020 | 49 | 0.620 |
Why?
|
| Viral Load | 8 | 2023 | 73 | 0.620 |
Why?
|
| Choice Behavior | 1 | 2020 | 88 | 0.600 |
Why?
|
| Health Services Accessibility | 4 | 2025 | 260 | 0.580 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2015 | 39 | 0.560 |
Why?
|
| Cameroon | 3 | 2022 | 4 | 0.550 |
Why?
|
| Prevalence | 8 | 2024 | 1034 | 0.540 |
Why?
|
| Adolescent | 11 | 2023 | 3799 | 0.530 |
Why?
|
| Middle Aged | 16 | 2025 | 12703 | 0.530 |
Why?
|
| Appalachian Region | 5 | 2025 | 20 | 0.510 |
Why?
|
| Marijuana Abuse | 1 | 2016 | 20 | 0.490 |
Why?
|
| Analgesics, Opioid | 6 | 2025 | 265 | 0.480 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2019 | 364 | 0.480 |
Why?
|
| Harm Reduction | 4 | 2019 | 16 | 0.460 |
Why?
|
| Interviews as Topic | 5 | 2025 | 272 | 0.450 |
Why?
|
| Continuity of Patient Care | 1 | 2016 | 75 | 0.450 |
Why?
|
| Pregnancy Outcome | 1 | 2015 | 96 | 0.440 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 245 | 0.440 |
Why?
|
| Mental Disorders | 2 | 2025 | 127 | 0.400 |
Why?
|
| Virus Replication | 1 | 2013 | 43 | 0.400 |
Why?
|
| Urethritis | 2 | 2023 | 3 | 0.380 |
Why?
|
| HIV-1 | 2 | 2023 | 46 | 0.370 |
Why?
|
| Ukraine | 6 | 2023 | 6 | 0.360 |
Why?
|
| Indonesia | 6 | 2023 | 8 | 0.360 |
Why?
|
| United States | 4 | 2025 | 4267 | 0.330 |
Why?
|
| Substance Abuse Treatment Centers | 2 | 2020 | 2 | 0.330 |
Why?
|
| Focus Groups | 2 | 2020 | 125 | 0.300 |
Why?
|
| Unsafe Sex | 3 | 2017 | 23 | 0.280 |
Why?
|
| Cohort Studies | 4 | 2025 | 1910 | 0.270 |
Why?
|
| Developing Countries | 2 | 2025 | 60 | 0.260 |
Why?
|
| Comorbidity | 2 | 2025 | 596 | 0.240 |
Why?
|
| Pregnancy | 6 | 2023 | 1069 | 0.240 |
Why?
|
| Ambulatory Care Facilities | 3 | 2023 | 87 | 0.240 |
Why?
|
| Substance Abuse Detection | 1 | 2025 | 10 | 0.230 |
Why?
|
| Fentanyl | 1 | 2025 | 37 | 0.220 |
Why?
|
| Oregon | 1 | 2025 | 8 | 0.220 |
Why?
|
| Tuberculosis | 2 | 2023 | 17 | 0.220 |
Why?
|
| Treatment Outcome | 6 | 2020 | 3618 | 0.220 |
Why?
|
| Bayes Theorem | 1 | 2024 | 85 | 0.210 |
Why?
|
| Patient Participation | 1 | 2025 | 93 | 0.210 |
Why?
|
| Central Nervous System Stimulants | 1 | 2024 | 85 | 0.210 |
Why?
|
| Child Abuse | 1 | 2024 | 28 | 0.200 |
Why?
|
| Homosexuality, Female | 1 | 2023 | 11 | 0.200 |
Why?
|
| Pilot Projects | 1 | 2025 | 583 | 0.200 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2023 | 49 | 0.190 |
Why?
|
| Contraception | 1 | 2022 | 13 | 0.190 |
Why?
|
| Peer Group | 1 | 2022 | 45 | 0.180 |
Why?
|
| Safe Sex | 2 | 2019 | 14 | 0.180 |
Why?
|
| Perception | 2 | 2020 | 107 | 0.180 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2018 | 34 | 0.180 |
Why?
|
| Sex Offenses | 1 | 2021 | 2 | 0.180 |
Why?
|
| Crime Victims | 1 | 2021 | 10 | 0.180 |
Why?
|
| Asthma | 1 | 2023 | 274 | 0.170 |
Why?
|
| Psychotherapy, Brief | 1 | 2020 | 5 | 0.170 |
Why?
|
| Zimbabwe | 2 | 2022 | 22 | 0.160 |
Why?
|
| Africa South of the Sahara | 2 | 2019 | 22 | 0.160 |
Why?
|
| Interinstitutional Relations | 1 | 2020 | 13 | 0.160 |
Why?
|
| Influenza Vaccines | 1 | 2021 | 90 | 0.160 |
Why?
|
| Behavior, Addictive | 1 | 2020 | 40 | 0.160 |
Why?
|
| Emergency Medical Technicians | 1 | 2020 | 13 | 0.160 |
Why?
|
| Risk-Taking | 2 | 2017 | 97 | 0.160 |
Why?
|
| Treponema pallidum | 1 | 2020 | 7 | 0.160 |
Why?
|
| Syphilis | 1 | 2020 | 11 | 0.160 |
Why?
|
| Intention | 1 | 2020 | 31 | 0.160 |
Why?
|
| Papillomaviridae | 1 | 2020 | 23 | 0.160 |
Why?
|
| Influenza, Human | 1 | 2021 | 133 | 0.160 |
Why?
|
| Cooperative Behavior | 1 | 2020 | 87 | 0.150 |
Why?
|
| Sleep | 1 | 2020 | 90 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 565 | 0.150 |
Why?
|
| Clinical Clerkship | 1 | 2019 | 42 | 0.150 |
Why?
|
| Papillomavirus Infections | 1 | 2020 | 71 | 0.150 |
Why?
|
| Uganda | 2 | 2015 | 9 | 0.150 |
Why?
|
| Heterosexuality | 1 | 2018 | 15 | 0.140 |
Why?
|
| Suicide, Attempted | 1 | 2018 | 33 | 0.140 |
Why?
|
| Sex Factors | 1 | 2020 | 707 | 0.140 |
Why?
|
| Patient-Centered Care | 1 | 2019 | 77 | 0.140 |
Why?
|
| Prenatal Care | 2 | 2015 | 55 | 0.140 |
Why?
|
| Mental Health | 3 | 2025 | 126 | 0.140 |
Why?
|
| Serologic Tests | 1 | 2018 | 11 | 0.140 |
Why?
|
| Health Personnel | 1 | 2019 | 131 | 0.140 |
Why?
|
| Child | 5 | 2024 | 2613 | 0.130 |
Why?
|
| Prospective Studies | 3 | 2022 | 2461 | 0.130 |
Why?
|
| Malnutrition | 1 | 2016 | 21 | 0.130 |
Why?
|
| Health Services | 1 | 2016 | 42 | 0.120 |
Why?
|
| Patient Selection | 1 | 2018 | 291 | 0.120 |
Why?
|
| Anxiety | 3 | 2023 | 206 | 0.120 |
Why?
|
| Resource Allocation | 1 | 2016 | 9 | 0.120 |
Why?
|
| Government Programs | 1 | 2016 | 11 | 0.120 |
Why?
|
| Ethics, Research | 1 | 2016 | 25 | 0.120 |
Why?
|
| Disease Transmission, Infectious | 1 | 2016 | 18 | 0.120 |
Why?
|
| Preventive Health Services | 1 | 2016 | 39 | 0.120 |
Why?
|
| Pregnancy Rate | 1 | 2015 | 11 | 0.120 |
Why?
|
| Health Services Research | 1 | 2016 | 82 | 0.120 |
Why?
|
| Community Networks | 1 | 2015 | 26 | 0.110 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2015 | 25 | 0.110 |
Why?
|
| Community Health Services | 1 | 2015 | 50 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 318 | 0.110 |
Why?
|
| Retrospective Studies | 1 | 2022 | 3812 | 0.110 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2014 | 2 | 0.110 |
Why?
|
| Antitubercular Agents | 1 | 2014 | 8 | 0.100 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2014 | 24 | 0.100 |
Why?
|
| Giardiasis | 1 | 2014 | 1 | 0.100 |
Why?
|
| Giardia lamblia | 1 | 2014 | 2 | 0.100 |
Why?
|
| Bacteriological Techniques | 1 | 2014 | 16 | 0.100 |
Why?
|
| Dog Diseases | 1 | 2014 | 12 | 0.100 |
Why?
|
| Dogs | 1 | 2014 | 130 | 0.100 |
Why?
|
| Feasibility Studies | 3 | 2019 | 323 | 0.100 |
Why?
|
| Malaria Vaccines | 1 | 2012 | 1 | 0.100 |
Why?
|
| Malaria | 1 | 2012 | 13 | 0.100 |
Why?
|
| Immunization Schedule | 1 | 2012 | 27 | 0.100 |
Why?
|
| Semen | 2 | 2023 | 10 | 0.090 |
Why?
|
| RNA, Viral | 2 | 2021 | 49 | 0.080 |
Why?
|
| HIV | 2 | 2023 | 26 | 0.080 |
Why?
|
| Students | 2 | 2021 | 178 | 0.080 |
Why?
|
| Methadone | 2 | 2020 | 12 | 0.080 |
Why?
|
| Ethanol | 2 | 2021 | 198 | 0.070 |
Why?
|
| Policy Making | 2 | 2019 | 20 | 0.070 |
Why?
|
| Program Evaluation | 2 | 2020 | 190 | 0.070 |
Why?
|
| Age Factors | 2 | 2020 | 1261 | 0.060 |
Why?
|
| Quality of Life | 2 | 2023 | 1032 | 0.060 |
Why?
|
| Infant | 3 | 2015 | 1122 | 0.060 |
Why?
|
| Research Design | 2 | 2020 | 337 | 0.060 |
Why?
|
| New York | 1 | 2025 | 23 | 0.060 |
Why?
|
| Incidence | 2 | 2018 | 1288 | 0.050 |
Why?
|
| Child Welfare | 1 | 2024 | 25 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2024 | 193 | 0.050 |
Why?
|
| Urban Population | 1 | 2023 | 97 | 0.050 |
Why?
|
| Anxiety Disorders | 1 | 2023 | 81 | 0.050 |
Why?
|
| Psychometrics | 1 | 2023 | 143 | 0.050 |
Why?
|
| Contraceptive Agents | 1 | 2022 | 4 | 0.050 |
Why?
|
| Risk Factors | 2 | 2023 | 4136 | 0.050 |
Why?
|
| Democratic Republic of the Congo | 1 | 2022 | 2 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2022 | 6 | 0.050 |
Why?
|
| Virus Shedding | 1 | 2021 | 5 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2015 | 730 | 0.040 |
Why?
|
| Aged | 2 | 2025 | 10998 | 0.040 |
Why?
|
| Schools | 1 | 2021 | 67 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 819 | 0.040 |
Why?
|
| Buprenorphine | 1 | 2020 | 14 | 0.040 |
Why?
|
| Universities | 1 | 2021 | 152 | 0.040 |
Why?
|
| North Carolina | 1 | 2024 | 1612 | 0.040 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2020 | 4 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2020 | 10 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2020 | 33 | 0.040 |
Why?
|
| Vaccination | 1 | 2021 | 153 | 0.040 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2020 | 44 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2014 | 1354 | 0.040 |
Why?
|
| Naloxone | 1 | 2019 | 33 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2020 | 133 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2020 | 149 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 230 | 0.040 |
Why?
|
| Self Care | 1 | 2020 | 144 | 0.040 |
Why?
|
| Angola | 1 | 2018 | 1 | 0.040 |
Why?
|
| Anal Canal | 1 | 2018 | 35 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 261 | 0.040 |
Why?
|
| Depressive Disorder | 1 | 2018 | 76 | 0.030 |
Why?
|
| Time | 1 | 2018 | 29 | 0.030 |
Why?
|
| HIV Antibodies | 1 | 2018 | 2 | 0.030 |
Why?
|
| Russia | 1 | 2018 | 4 | 0.030 |
Why?
|
| Health Policy | 1 | 2019 | 96 | 0.030 |
Why?
|
| Directive Counseling | 1 | 2018 | 19 | 0.030 |
Why?
|
| Morals | 1 | 2017 | 7 | 0.030 |
Why?
|
| Public Health | 1 | 2019 | 94 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 801 | 0.030 |
Why?
|
| Needle Sharing | 1 | 2017 | 1 | 0.030 |
Why?
|
| Criminals | 1 | 2017 | 2 | 0.030 |
Why?
|
| Marital Status | 1 | 2017 | 22 | 0.030 |
Why?
|
| Curriculum | 1 | 2019 | 217 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 193 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 378 | 0.030 |
Why?
|
| Research | 1 | 2017 | 88 | 0.030 |
Why?
|
| Employment | 1 | 2017 | 52 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2018 | 250 | 0.030 |
Why?
|
| Homosexuality, Male | 1 | 2018 | 105 | 0.030 |
Why?
|
| Educational Status | 1 | 2017 | 185 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 803 | 0.030 |
Why?
|
| Patient Rights | 1 | 2016 | 12 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2016 | 40 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 446 | 0.030 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2015 | 4 | 0.030 |
Why?
|
| South Africa | 1 | 2015 | 14 | 0.030 |
Why?
|
| Gender Identity | 1 | 2015 | 28 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2015 | 62 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2015 | 40 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2015 | 47 | 0.030 |
Why?
|
| Travel | 1 | 2015 | 15 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2016 | 138 | 0.030 |
Why?
|
| Motor Vehicles | 1 | 2015 | 25 | 0.030 |
Why?
|
| Tanzania | 1 | 2014 | 12 | 0.030 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2014 | 6 | 0.030 |
Why?
|
| Arizona | 1 | 2014 | 8 | 0.030 |
Why?
|
| Feces | 1 | 2014 | 43 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 142 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 204 | 0.020 |
Why?
|
| Mozambique | 1 | 2012 | 1 | 0.020 |
Why?
|
| Genotype | 1 | 2014 | 743 | 0.020 |
Why?
|
| Decision Making | 1 | 2014 | 203 | 0.020 |
Why?
|
| Animals | 1 | 2014 | 8544 | 0.010 |
Why?
|